Roswell Park Comprehensive Cancer Center

Phase 1 study to determine the safety and feasibility of using HERV-E TCR-transduced autologous T Cells in patients with metastatic clear-cell renal-cell carcinoma.

Phase 1 study of adoptive immunotherapy with CD8+ and CD4+ memory T cells transduced to express an HA-1-specific T cell receptor for children and adults with recurrent acute leukemia after allogeneic hematopoietic stem cell transplantation.

Phase 1 dose-escalation clinical trial to determine the phase 2 dose of autologous TIL 1383I TCR gene-modified T cells using a retrovirus for patients with advanced melanoma.

Ovarian Cancer Research Alliance presented its Rosalind Franklin Prize for Excellence in Ovarian Cancer Research to Kunle Odunsi, MD, PhD, FRCOG, FACOG.

CHICAGO — Patients with anti-PD-1-naive triple-negative breast cancer and PD-1-relapsed or refractory melanoma demonstrated antitumor benefit from MIW815 plus spartalizumab, according to results of a phase 1b study presented at ASCO Annual Meeting.

ATLANTA — Oral contraceptive use appeared associated with a reduced risk for highly fatal aggressive ovarian cancer, with a greater risk reduction observed with longer birth control use, according to study results presented at American Association for Cancer Research Annual Meeting.

A restrictive protocol safely and effectively reduced the number of opioids prescribed to patients who underwent gynecologic or abdominal surgery, according to findings from a 2-year pilot case-control study.

Minimally invasive surgeries have emerged as often-preferable alternatives to open surgeries for a variety of malignancies, due to the lower risk for complications and faster time to recovery.

The Cuban-developed immunotherapy CIMAvax-EGF in combination with nivolumab appeared safe for patients with advanced non-small cell lung cancer, according to results from the first portion of a phase 1/phase 2 trial.

Igor Puzanov, MD, MSCI, FACP, received the Melanoma Foundation Award for outstanding and lifelong contributions to melanoma research.